Payment overview · 2025
General Payments
$34.55
1 reported records · 1 companies
Healthcare provider profile · identity verified
Arnold Leon Weg, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology · FOREST HILLS, NY · NPI 1417961814
Verified facts
What the public records show
CMS Open Payments records show Arnold Leon Weg, MD received $34.55 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.55 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $34.55 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1121 | 309 |
| Atorvastatin Calcium | Atorvastatin Calcium | 895 | 253 |
| Pantoprazole Sodium | Pantoprazole Sodium | 629 | 198 |
| Losartan Potassium | Losartan Potassium | 371 | 108 |
| Ezetimibe | Ezetimibe | 361 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 335 | 95 |
| Candesartan Cilexetil | Candesartan Cilexetil | 322 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 82 |
| Simvastatin | Simvastatin | 277 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 263 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 257 | 72 |
| Omeprazole | Omeprazole | 255 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 73 |
| Metformin Hcl Er | Metformin Hcl | 226 | 70 |
| Meloxicam | Meloxicam | 205 | 64 |
| Fenofibrate | Fenofibrate Nanocrystallized | 200 | 62 |
| Eliquis | Apixaban | 169 | 36 |
| Alprazolam | Alprazolam | 167 | 43 |
| Lorazepam | Lorazepam | 156 | 43 |
| Synthroid | Levothyroxine Sodium | 153 | 44 |
| Trazodone Hcl | Trazodone Hcl | 150 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 49 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 145 | 143 |
| Metformin Hcl | Metformin Hcl | 142 | 42 |
| Dexlansoprazole Dr | Dexlansoprazole | 130 | 36 |
| Gabapentin | Gabapentin | 127 | 44 |
| Valsartan | Valsartan | 116 | 32 |
| Clonazepam | Clonazepam | 111 | 23 |
| Jardiance | Empagliflozin | 109 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 27 |
| Montelukast Sodium | Montelukast Sodium | 94 | 27 |
| Allopurinol | Allopurinol | 93 | 24 |
| Torsemide | Torsemide | 85 | 27 |
| Mounjaro | Tirzepatide | 84 | 19 |
| Clonidine Hcl | Clonidine Hcl | 83 | 20 |
| Donepezil Hcl | Donepezil Hcl | 83 | 22 |
| Famotidine | Famotidine | 82 | 33 |
| Ozempic | Semaglutide | 81 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 35 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 76 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 74 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 71 | 20 |
| Finasteride | Finasteride | 70 | 18 |
| Silodosin | Silodosin | 70 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 68 | 16 |
| Atenolol | Atenolol | 68 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 21 |
| Lisinopril | Lisinopril | 67 | 16 |
| Myrbetriq | Mirabegron | 67 | 17 |
| Memantine Hcl | Memantine Hcl | 65 | 18 |
| Mirtazapine | Mirtazapine | 64 | 16 |
| Rabeprazole Sodium | Rabeprazole Sodium | 63 | 16 |
| Trulicity | Dulaglutide | 63 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 18 |
| Tramadol Hcl | Tramadol Hcl | 60 | 26 |
| Dutasteride | Dutasteride | 59 | 13 |
| Glimepiride | Glimepiride | 58 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 53 | 31 |
| Bupropion Hcl Sr | Bupropion Hcl | 52 | 14 |
| Cefuroxime | Cefuroxime Axetil | 52 | 41 |
| Sertraline Hcl | Sertraline Hcl | 50 | 14 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 50 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 40 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 19 |
| Spironolactone | Spironolactone | 44 | 13 |
| Valacyclovir | Valacyclovir Hcl | 44 | 21 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 43 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 30 |
| Raloxifene Hcl | Raloxifene Hcl | 39 | 11 |
| Chlorthalidone | Chlorthalidone | 38 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 27 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 19 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Furosemide | Furosemide | 24 | 12 |
| Niacin Er | Niacin | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Triazolam | Triazolam | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Budesonide Er | Budesonide | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 13 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 15 |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Dexilant | Dexlansoprazole | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | 11 |
| Linzess | Linaclotide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Alosetron Hcl | Alosetron Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Celebrex | Celecoxib | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Prednisone | Prednisone | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Toprol Xl | Metoprolol Succinate | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Sutab | Sod Sulf/Pot Chloride/Mag Sulf | 11 | 11 |
| Ursodiol | Ursodiol | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34.55 · 1 records | Novo Nordisk Inc | Ozempic | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error